Undisclosed Program 2 (BMS)
Undisclosed
DiscoveryPartnered
Key Facts
About AI Proteins
AI Proteins is an early-stage biotech leveraging a proprietary AI-driven platform to design novel miniprotein therapeutics from scratch. The company's closed-loop engine integrates generative AI design, automated synthesis, and lab validation to rapidly create and optimize drug candidates with desired properties like high stability, low immunogenicity, and precise targeting. With a pipeline targeting over 150 drug targets and a significant partnership with Bristol Myers Squibb, AI Proteins is positioning itself at the forefront of next-generation biologic drug discovery.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |